期刊
MOLECULAR MECHANISMS OF NEURODEGENERATION
卷 65, 期 7, 页码 885-904出版社
PORTLAND PRESS LTD
DOI: 10.1042/EBC20210021
关键词
-
资金
- University Hospital Bonn
Neurodegenerative diseases pose challenges in treatment due to the critical role of neuroinflammation in disease progression. The activation of NLRP3 inflammasome plays a significant role in various neuroinflammatory diseases, and inhibitors have shown promising results in preclinical models. The understanding of NLRP3 inhibitors as a therapeutic target in neurodegenerative diseases is supported by current research.
Approximately ten million people are diagnosed with dementia annually since they experience difficulties with memory and thinking skills. Since neurodegenerative diseases are diagnosed late, most of them are difficult to treat. This is due to the increased severity of the disease during the progression when neuroinflammation plays a critical role. The activation of immune cells, especially microglia, plays a crucial role in the development of neurodegenerative diseases. Molecular sensors within these microglia, such as the NLRP3 inflammasome, are activated by signals that represent the hallmarks of neurodegenerative diseases. Here, we first summarize the two activation steps of NLRP3 inflammasome activation. Furthermore, we discuss the key factors that contribute to NLRP3 inflammasome activation in the different neuroinflammatory diseases, like Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The prominent NLRP3 inflammasome triggers include amyloid beta and tau oligomers in AD, alpha-synuclein in PD, and superoxide dismutase (SOD1) and TAR DNA-binding protein 43 (TDP43) in ALS. NLRP3 inhibitor treatment has shown promising results in several preclinical mouse models of AD, PD, and ALS. Finally, we postulate that current understandings underpin the potential for NLRP3 inhibitors as a therapeutic target in neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据